Message Font: Serif | Sans-Serif
 
No. of Recommendations: 2
Company now trading at 6.7x revised downwards ebitda. I feel confident they can file accurate financials by April 30th. No lender wants to put them in anything close to BK.

PFE trades at 9x ebitda. Rest of pharma trades at 10-14x ebitda. Most of these are slow/no-growth firms.

If VRX files properly, gets its act together over the next 12-24 months -- they have very few maturities until 2018 -- you'd think it could trade up to 9x ebitda. Also they did not increase prices this year so going fwd, I think they can increase the traditional 6-10% that all the other pharmas do.

I don't know what the upside is, nor how long it would take to get there. Certainly, the time to generally buy is at the darkest point for numbers and news releases, and VRX could be there.

But, my #3 rule is don't buy turnarounds until they turn around.


No position.







ps Frankly, I think the bonds are a better bet as of today. It's not like VRX can waste their cash on another acquisition or borrow more, those days are over for a long time.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.